ABSTRACT
The elasmobranch bycatch of the Gulf of Papua Prawn Fishery is investigated in detail for the first time. Fisheries observers collected data on the elasmobranch bycatch from a total of 403 trawl sets (1,273 hrs) in the Gulf of Papua. A total of 40 species of elasmobranchs were recorded ranging in size from a 12 cm disc width stingray to a 350 cm total length sawfish. High mortality rates were recorded (>80%), attributed to the long trawl durations (up to 4 hours). The future inclusion of bycatch reduction devices would likely reduce the number of larger elasmobranchs being caught, based on evidence from the prawn trawl fisheries of northern Australia, and is being investigated by the PNG National Fisheries Authority. Differences in catch compositions were detected across the management zones as well as between the two monsoonal seasons (SE Monsoon and NW Monsoon). Increased monitoring and additional research is required and management plans should address the elasmobranch bycatch and in particular their high mortality rate.
ABSTRACT
In a step-up approach of DMARD treatment of RA a fast response and an early DMARD switch in the case of non-response is important. Therefore, we performed an open trial in which we compared an 8-week and a 16-week observation period during treatment of RA with MTX or LEF, both given in intensified starting doses and accompanied by moderate dose prednisone. MTX and LEF naïve patients with RA (mean time since diagnosis: 2.3 years) were randomised to receive either LEF in a 3-day-loading dose of 100 mg/day followed by 20 mg/day (n = 19) or MTX intramuscularly in a dose of 25 mg once weekly (n = 21). All patients received concomitant treatment with oral prednisone in an initial dose of 20 mg/day with weekly dose reductions of 5 mg/day. The disease activity was re-evaluated 8 and 16 weeks after the start of the treatment. Mean DAS28 before the start of treatment was 5.36 +/- 0.8 for the MTX-group and 5.46 +/- 0.8 for the LEF-group. After 8 weeks of treatment the DAS28 in the MTX-group was 2.59 +/- 1.0 and 3.16 +/- 0.8 in the LEF group (difference not significant). The mean DAS28 at re-evaluation 16 weeks after the starting of treatment (2.58 +/- 1.5 for the MTX-group and 3.25 +/- 1.16 for the LEF-group) was significantly different neither in between the both treatment groups nor in comparison to the week 8 evaluation. Efficiency of RA treatment with MTX or LEF in intensified doses and in combination with moderate dose prednisone can be sufficiently judged 8 weeks after its initiation.
